The ethics of expanding access to cheaper, less effective treatments

Lancet. 2016 Aug 27;388(10047):932-4. doi: 10.1016/S0140-6736(15)01025-9. Epub 2016 Apr 20.

Authors

Govind C Persad¹, Ezekiel J Emanuel²

Affiliations

¹ Department of Strategy, Economics, Ethics, and Public Policy, McDonough School of Business, Georgetown University, Washington, DC, USA.
² Office of the Provost, Department of Medical Ethics and Health Policy, Department of Health Care Management, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; The Wharton School, University of Pennsylvania, Philadelphia, PA, USA. Electronic address: MEHPchair@upenn.edu.

PMID: 27108231
DOI: 10.1016/S0140-6736(15)01025-9

No abstract available

MeSH terms

Anti-HIV Agents / administration & dosage
Anti-HIV Agents / adverse effects
Anti-HIV Agents / economics*
Anti-HIV Agents / therapeutic use*
Antiretroviral Therapy, Highly Active
Developed Countries
Developing Countries
Drug Administration Schedule
Ethical Theory
Global Health / economics
Global Health / ethics*
Global Health / standards
Global Health / trends
HIV Infections / drug therapy*
HIV Infections / economics*
Health Services Accessibility / economics*
Health Services Accessibility / ethics*
Health Services Accessibility / standards
Health Services Accessibility / trends
Humans
South Africa
Stavudine / economics
Stavudine / therapeutic use
Tenofovir / economics
Tenofovir / therapeutic use
Treatment Outcome
United States
United States Food and Drug Administration
World Health Organization
Zidovudine / economics
Zidovudine / therapeutic use

Substances

Anti-HIV Agents
Zidovudine
Tenofovir
Stavudine